Opinion|Videos|March 13, 2025
TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)
Experts discuss the patient demographics and clinical trial design of the phase 2b SunRISe-1 study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 inhibitor), with results presented at the recent European Society for Medical Oncology 2024 Congress, as well as the safety and efficacy data from the SunRISe-1 trial.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- SunRISe-1 is a phase 2b study investigating the use of TAR-200 as a monotherapy and in combination with cetrelimab (a PD-1 inhibitor), with results presented at the recent European Society for Medical Oncology 2024 Congress. Discuss patient demographics and SunRISe-1 clinical trial design.
- Discuss the safety and efficacy data from the SunRISe-1 trial.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
3
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
4
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
5
